Scilex prelim Q1: ZTlido gross sales $34-38M (+24-38% YoY); net sales $12-13M (+13-23% YoY)

Scilex Holding Co

2024-Q1 EPS reported -$0.24 revenue$10,884,000

ZTlido gross sales Q1 2024 estimated $34-38M vs $27.5M Q1 2023, up 24-38%.
ZTlido net sales Q1 2024 estimated $12-13M vs $10.6M Q1 2023, up 13-23%.
Company plans to cut R&D and admin expenses in 2024; focuses on late-stage pipeline like SP-102.
Change Healthcare co-pay processing for ZTlido restored to normal after cyber disruption.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Scilex Holding Co reported quarter ended March 31, 2024 results: revenue ZTlido gross sales for the first quarter of 2024 were in the range of $34.0 million to $38.0 million.

Period: quarter ended March 31, 2024
Revenue: ZTlido gross sales for the first quarter of 2024 were in the range of $34.0 million to $38.0 million
Result: preliminary results

Exact text from the filing

Scilex Holding Company (the “Company”) is providing certain preliminary unaudited financial results for the quarter ended March 31, 2024 based on currently available information.

View on SEC.gov

548 earnings releases filed in the last 30 days. Browse all earnings releases →

Scilex Holding Co filing history →

Source: SEC EDGAR

accession 0001193125-24-097730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.